CTLA4-Ig: a novel immunosuppressive agent. - Wikidata - wikimedia - TriplyDB

CTLA4-Ig: a novel immunosuppressive agent.

CTLA4-Ig: a novel immunosuppressive agent.

http://www.wikidata.org/entity/Q34075083

about

Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets Effects of RNA interference on CD80 and CD86 expression in bone marrow-derived murine dendritic cells.Ctla-4 gene polymorphism in +49 a/g position: a case control study on patients with oral lichen planus.Novel immune-based therapies for psoriasis.TIM4 Regulates the Anti-Islet Th2 Alloimmune Response T-cells and B-cells in osteoporosis T cell costimulatory pathways: blockade for autoimmunity.Immunopathology and the gene therapy of lupus.Novel biological immunotherapies for psoriasis.Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases.Altering immune tolerance therapeutically: the power of negative thinking.Inhibition of arterial allograft intimal hyperplasia using recipient dendritic cells pretreated with B7 antisense peptide.CTLA4 enhances the osteogenic differentiation of allogeneic human mesenchymal stem cells in a model of immune activation.Genome-Wide Association Studies in Primary Biliary Cirrhosis.Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model.Novel gene therapeutic strategies for the induction of tolerance in cornea transplantation.Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential.Parathyroid Diseases and T Cells.Proceedings: Immune Tolerance and Stem Cell Transplantation: A CIRM Mini-Symposium and Workshop Report.Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis.Comparative Efficacies of Long-Term Serial Transplantation of Syngeneic, Allogeneic, Xenogeneic, or CTLA4Ig-Overproducing Xenogeneic Adipose Tissue-Derived Mesenchymal Stem Cells on Murine Systemic Lupus Erythematosus.Allogenic donor splenocytes pretreated with antisense peptide against B7 prolong cardiac allograft survival

P2860

Q24811473-4043E072-B9A0-41B7-82EC-EA33A2967D4E Q26830569-65B25146-2F93-42B2-A70A-CDDB83D0AE3D Q33262644-78041E6B-C8F4-4691-802B-D6784E314987 Q34500412-3272105A-946E-48D2-8094-0347E5AC580C Q34609477-9F0D60CA-069E-49FB-87BB-B4BCFC5C0FD9 Q34791435-A084A8FC-29AB-4CE1-A4D9-3EC282FE573C Q35035665-2BB241CA-B82B-4CCA-9C2D-F1D62767F38A Q35093604-16C2ED2C-7103-45EF-A975-13C351A9DEB1 Q35122166-8202E2FA-985C-401A-8CF2-126471458F9A Q35164740-62C61A4A-AF2D-4E01-A104-91492010346C Q35581131-978CC835-1637-4A70-95CF-66F9490C6ACF Q35600811-2465100F-1E9D-40B9-A0B5-3F31275FB99A Q35779718-1C07B6DF-C44A-4ABA-9733-A03DE48A9570 Q35881348-B91002F1-E96C-49BA-BF89-C0DE8B509DCD Q36383011-0D6131E7-DDBC-408F-B3FF-CE1631D797A9 Q36593078-DE42AFEF-2B75-4AAE-BC54-DA45F9C1C062 Q37715449-2C893BBC-DDDA-4E25-8571-FAF7E331BEA3 Q37755334-B56DDF33-5230-4231-9554-1F8EDC833FE2 Q38620803-92194431-6E85-47E7-A44B-D32000019BFD Q39249931-9EC56A5B-3446-4CA3-B21B-0EFE9574B657 Q42552506-397D4969-B350-4DD5-BA51-6BFD8E5AE177 Q44607823-82A19A37-81BB-47DF-83ED-20C78903E3E7 Q52916537-992C05F2-C75C-45EF-8BB6-4BECBD0AFFE1 Q56903240-7FAC6ACD-7828-4506-A9ED-3B0DE7392025

P2860

CTLA4-Ig: a novel immunosuppressive agent.

http://www.wikidata.org/entity/Q34075083

description

2000 nî lūn-bûn

@nan

2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

CTLA4-Ig: a novel immunosuppressive agent.

@ast

CTLA4-Ig: a novel immunosuppressive agent.

@en

CTLA4-Ig: a novel immunosuppressive agent.

@nl

type

label

CTLA4-Ig: a novel immunosuppressive agent.

@ast

CTLA4-Ig: a novel immunosuppressive agent.

@en

CTLA4-Ig: a novel immunosuppressive agent.

@nl

prefLabel

CTLA4-Ig: a novel immunosuppressive agent.

@ast

CTLA4-Ig: a novel immunosuppressive agent.

@en

CTLA4-Ig: a novel immunosuppressive agent.

@nl

P1433

Q34075083-A2A0F7D4-6A25-44B2-8E86-11ABBF1D88FC

P1476

Q34075083-A7D6CD45-1251-43AE-A958-54C106CB5A31

P2093

Q34075083-3D664243-E969-494B-82D5-693CD6D3C567

Q34075083-691D98EC-CAB6-4432-9E24-692ED8DB8C20

P2860

Q34075083-07289466-006A-488A-86CB-360BD3543EE1

Q34075083-0AA01176-4BFD-4469-8CDA-EF1D3FE2DF03

Q34075083-171A5DA1-9859-43C6-A622-1476CA95BEB1

Q34075083-1AE6E501-FD93-493E-8C37-695236AD04D2

Q34075083-1F5E1900-1B13-4BD9-B35C-87436ECDCDAE

Q34075083-21874A1E-C0F9-4B21-8B73-A49A2DCAD820

Q34075083-227212D8-FE35-4BC0-BECB-17E9CD60A93B

Q34075083-270EBFC0-9DD8-4F86-95FA-0C8891DA9A3F

Q34075083-2822FFB5-CAFB-45CC-BB3D-3775CB958372

Q34075083-4C4E8D8E-E111-4B58-AB4C-11F3664A4618

P304

Q34075083-3D1381E8-8D60-4D8E-AC0E-639E07098C22

P31

Q34075083-86F720A4-28A4-4654-ABD5-F2383173FE05

P356

Q34075083-8B0409B8-30BA-403A-B30F-7FA3FC05E6DC

P407

Q34075083-C9376E90-AAE0-48A8-9D52-0C3F47596336

P433

Q34075083-DCEC29C6-E18A-4693-9F54-D3A26305CF00

P478

Q34075083-3C1241D0-761E-4684-A23F-84E1A23EF36F

P577

Q34075083-D21C99D2-F0C9-4DBE-8451-85A1233A6600

P698

Q34075083-1793A18C-F689-4F42-B63D-8A4B2AF7B9EC

P356

13543784.9.9.2147

P1433

Expert Opinion on Investigational Drugs

P1476

CTLA4-Ig: a novel immunosuppressive agent.

@en

P2093

M H Sayegh

http://www.w3.org/2001/XMLSchema#string

N Najafian

http://www.w3.org/2001/XMLSchema#string

P2860

CD28/B7 system of T cell costimulation

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

CTLA-4 can function as a negative regulator of T cell activation

The role of the CD28 receptor during T cell responses to antigen

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

The mechanism of action of cyclosporin A and FK506

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis.

Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells.

Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.

P304

2147-2157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.9.9.2147

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2000-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11060799

http://www.w3.org/2001/XMLSchema#string